NEWRON PHARMACEUT. EO-20 (NP5) — Tangible Net Worth Ratio
NEWRON PHARMACEUT. EO-20 (NP5) has a Tangible Net Worth Ratio of 100.0% as of June 2025. This metric is calculated by deducting intangible assets (€0.00) from net assets (€1.58 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See NP5 net asset value for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
NEWRON PHARMACEUT. EO-20 Tangible Net Worth Ratio (2021–2024)
This chart shows how NEWRON PHARMACEUT. EO-20's Tangible Net Worth Ratio has changed across 2 annual periods from 2021 to 2024. As of June 2025, the ratio stands at 100.0%, reflecting net assets of €1.58 Million with intangible assets of €0.00 EUR. Also explore net asset momentum of NEWRON PHARMACEUT. EO-20 to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for NEWRON PHARMACEUT. EO-20 (2021–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for NEWRON PHARMACEUT. EO-20 from 2021 to 2024, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see NEWRON PHARMACEUT. EO-20 stock valuation.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 100.0% | €1.46 Million | €0.00 | €63.91 Million | ▲ +0.0 pp |
| 2021 | 100.0% | €3.11 Million | €0.00 | €50.49 Million | — |